Enhancing TB Therapy with Precision: Immunomodulatory Nanoparticles Co-Delivering Rifampicin and Vitamin D3 for Macrophage-Targeted Treatment
Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5502-5519
DOI: 10.1021/acs.molpharmaceut.6c00601 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 14.10.2026. Verfasst von Leon J Khoza und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Scienc…. Hauptthemen laut MEDLINE: Rifampin, Cholecalciferol, Nanoparticles, Macrophages, Alveolar. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: South African Medical Research Council, National Research Foundation.
Abstract (Originalsprache)
Tuberculosis (TB) remains a leading cause of death worldwide, with over 6.2 million cases and nearly 2 million deaths annually. Despite available chemotherapies, significant challenges persist, including prolonged treatment, poor compliance, and the rise of multidrug-resistant (MDR) strains. This study developed a biocompatible, multifunctional drug-delivery system using 1,3-β-glucan-functionalized chitosan-polycaprolactone nanoparticles (1,3-β-Glu-CS-PCL) for co-delivery of Rifampicin (RIF) and Vitamin D3 (VITD3) to alveolar macrophages. Reactive oxygen species (ROS) generation was enhanced by Glu-CS-PCL-RIF (1.5- to 1.8-fold) and Glu-CS-PCL-VITD3 (1.7-fold higher than non-functionalized nanoparticles). Glu-CS-PCL-VITD3 also stimulated TNF-α secretion (1.8-fold increase), indicating a shift in the immune response towards macrophage activation. Minimum inhibitory concentration (MIC) studies showed superior bactericidal activity of Glu-CS-PCL-RIF against a drug-susceptible laboratory strain and clinically resistant isolates of Mycobacterium tuberculosis (Mtb), with a MIC of 0.00149 μg/mL, 2-fold lower than that of standard RIF. The combination of RIF and VITD3 demonstrated significant potency against drug-resistant TB with an effective dose 4x lower than standard treatment. Intracellular killing studies in THP-1 macrophages revealed that CS-PCL-RIF significantly reduced Mtb CFU counts (while containing approximately 15 times less RIF than the standard 50 μg/mL treatment). Glu-CS-PCL-VITD3 showed a notable reduction in CFUs compared to non-functionalized counterparts, illustrating the impact of 1,3-β-glucan functionalization. In conclusion, these multifunctional nanoparticles demonstrate strong potential for targeted anti-TB therapy by combining immunomodulation with enhanced antibacterial efficacy for future clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg2193, South Africa.
- Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg2193, South Africa.
- School of Pharmacy, Faculty of Natural Sciences, University of the Western Cape, Bellville7535, South Africa.
- School of Pathology, Faculty of Health Sciences, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg2193, South Africa.
ORCID-Profile: Leon J Khoza, Pradeep Kumar, Admire Dube, Yahya E Choonara
Förderung
- South African Medical Research Council
- National Research Foundation
Zitieren
APA
Khoza, L. J., Kumar, P., Dube, A., Gordhan, B. G., Kana, B. D., & Choonara, Y. E. (2026). Enhancing TB Therapy with Precision: Immunomodulatory Nanoparticles Co-Delivering Rifampicin and Vitamin D3 for Macrophage-Targeted Treatment. Molecular Pharmaceutics, 23(11), 5502-5519. https://doi.org/10.1021/acs.molpharmaceut.6c00601
Vancouver
Khoza LJ, Kumar P, Dube A, Gordhan BG, Kana BD, Choonara YE. Enhancing TB Therapy with Precision: Immunomodulatory Nanoparticles Co-Delivering Rifampicin and Vitamin D3 for Macrophage-Targeted Treatment. Molecular Pharmaceutics. 2026;23(11):5502-5519. doi:10.1021/acs.molpharmaceut.6c00601
BibTeX
@article{Khoza2026,
author = {Khoza, Leon J and Kumar, Pradeep and Dube, Admire and Gordhan, Bhavna G and Kana, Bavesh D and Choonara, Yahya E},
title = {Enhancing TB Therapy with Precision: Immunomodulatory Nanoparticles Co-Delivering Rifampicin and Vitamin D3 for Macrophage-Targeted Treatment},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {11},
pages = {5502--5519},
doi = {10.1021/acs.molpharmaceut.6c00601}
}
EUVIMED